Persistence of antibodies acquired by natural hepatitis E virus infection and effects of vaccination  Y.-Y. Su, S.-J. Huang, M. Guo, J. Zhao, H. Yu, W.-G. He, H.-M. Jiang, Y.-J. Wang, X.-F. Zhang, J.-P. Cai, C.-L. Yang, Z.-Z. Wang, F.-C. Zhu, T. Wu, J. Zhang, N.-S. Xia  Clinical Microbiology and Infection  Volume 23, Issue 5, Pages 336.e1-336.e4 (May 2017) DOI: 10.1016/j.cmi.2016.10.029 Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 Observed anti-HEV IgG levels of participants in group A (placebo recipients) and group B (vaccine recipients) from months 0 to 67. Data were further divided into four subgroups according to anti-HEV levels at month 0: A1 (0.077≤GMC<0.25 WU/mL), A2 (0.25≤GMC<0.50 WU/mL), A3 (0.50≤GMC<1.0 WU/mL) and A4 (GMC≥1.0 WU/mL). In group B, participants who received doses 1, 2 and 3 of Hecolin were grouped into subgroup B1; those who received only dose 1 were included in subgroup B2; those who received doses 1 and 2 were included in subgroup B3; and those who received doses 1 and 3 were included in subgroup B4. HEV, hepatitis E virus; GMC, geometric mean concentration; Ig, immunoglobulin; WU, World Health Organization units. Clinical Microbiology and Infection 2017 23, 336.e1-336.e4DOI: (10.1016/j.cmi.2016.10.029) Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 2 Observed and predicted GMC and positive rate of anti-HEV IgG among participants in group A (placebo recipients) and group B1 (subgroup of vaccine recipients, who received 3 doses of Hecolin). (a, b) Observed and predicted GMC and positive rate among baseline seropositive placebo recipients (group A). Linear mixed effects model was used to predict long-term persistence of antibody level. (c, d) Observed and predicted GMC and positive rate among baseline seropositive participants who were vaccinated with 3 doses of Hecolin (group B1). Power-law model (dashed line) and modified power-law model (solid line) were fitted to predict long-term anti-HEV levels. HEV, hepatitis E virus; GMC, geometric mean concentration; Ig, immunoglobulin. Clinical Microbiology and Infection 2017 23, 336.e1-336.e4DOI: (10.1016/j.cmi.2016.10.029) Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions